View : 36 Download: 0
Efficacy and safety of gatifloxacin for urinary tract infection in nonspecialized Korean urologic practice
- Efficacy and safety of gatifloxacin for urinary tract infection in nonspecialized Korean urologic practice
- Lee S.D.; Lee S.J.; Hwang T.K.; Yoon D.K.; Lee K.S.; Sung L.H.; Choo M.S.; Shim B.S.; Cho I.R.; Kim M.E.; Ryu S.B.; Kim C.S.; Kim Y.G.; Kim C.I.; Rhew H.Y.; Kim M.H.; Cho Y.-H.
- Ewha Authors
- SCOPUS Author ID
- Issue Date
- Journal Title
- International Journal of Antimicrobial Agents
- vol. 28, no. SUPPL. 1, pp. 108 - 112
- SCI; SCIE; SCOPUS
- To investigate the efficacy and safety of gatifloxacin (400 mg/day) on chronic prostatitis or cystitis, 453 patients with prostatitis (NIH category II or IIIa) (N = 149, mean 45.8 ± 13.3 years) and cystitis (N = 304, mean 53.8 ± 14.3 years) were enrolled. Total NIH CPSI score and symptom score for cystitis decreased from 20.3 to 9.9 (response rate 86.7%, 95% CI 80.2-93.2%) and from 6.2 to 1.8 (response rate 83.2%, 95% CI 78.7-87.7%), respectively. In the overall clinical efficacy, 71.2% and 88.4% of the patients with prostatitis and cystitis were responders, respectively. Of the patients, 15.7% reported insignificant adverse events. These results suggest that gatifloxacin was well tolerated and improved the clinical outcomes in patients with chronic prostatitis or cystitis. © 2006 Elsevier B.V. and the International Society of Chemotherapy.
- Appears in Collections:
- 의과대학 > 의학과 > Journal papers
- Files in This Item:
There are no files associated with this item.
- RIS (EndNote)
- XLS (Excel)
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.